By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments
Company name ANSYS, Inc.
Stock ticker ANSS
Live stock price [stckqut]ANSS[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $81.19
Target stock price (averages with growth) $112.7
Target stock price (averages with no growth) $86.18
Target stock price (manual assumptions) $69.59

The following company description is from Google Finance: http://www.google.com/finance?q=anss

ANSYS, Inc. (ANSYS) develops and markets engineering simulation software and services used by engineers, designers, researchers and students across a range of industries and academia, including aerospace, automotive, manufacturing, electronics, biomedical, energy and defense. ANSYS focuses on the development of open and flexible solutions. The Company distributes its ANSYS suite of simulation technologies, through a global network of resellers and distributors (collectively, channel partners) and direct sales offices in global locations. The Company’s product portfolio consists of ANSYS Workbench, Multiphysics, Structural Mechanics, Fluid Dynamics, Explicit Dynamics, Electromagnetics, Simulation Process and Data Management, Academic, High-Performance Computing and Geometry Interfaces. In August 2011, the Company acquired Apache Design Solutions, Inc.

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments
Company name Alexion Pharmaceuticals, Inc.
Stock ticker ALXN
Live stock price [stckqut]ALXN[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $88.56
Target stock price (averages with growth) $106.34
Target stock price (averages with no growth) $58.39
Target stock price (manual assumptions) $88.59

The following company description is from Google Finance: http://www.google.com/finance?q=alxn

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer. Alexion’s marketed product, Soliris (eculizumab), is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). On January 28, 2011, Alexion acquired Taligen Therapeutics, Inc. (Taligen). On February 10, 2011, Alexion acquired patents and assets from Germany-based Orphatec Pharmaceuticals GmbH (Orphatec) related to an investigational therapy for patients with Type A molybdenum cofactor deficiency (MoCD).

Confident Investor comments: This company’s growth rate could actually dictate a much higher price than I am conservatively giving it. At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments
Company name Akamai Technologies, Inc.
Stock ticker AKAM
Live stock price [stckqut]AKAM[/stckqut]
P/E compared to competitors Good
MANAGEMENT EXECUTION
Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Fair
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $33.98
Target stock price (averages with growth) $51.56
Target stock price (averages with no growth) $44.54
Target stock price (manual assumptions) $27.48

The following company description is from Google Finance: http://www.google.com/finance?q=akam

Akamai Technologies, Inc. (Akamai) provides services for accelerating and improving the delivery of content and applications over the Internet; ranging from live and on-demand streaming video capabilities to conventional content on Websites, to tools that help people transact business and reach out to new and existing customers. Its services are used to sell, inform, entertain, market, advertise, deliver software and conduct their business online. It offers application performance services, services and solutions for digital media and software distribution and storage, content and application delivery, online advertising-related services and other specialized Internet-based offerings. In July 2010, the Company completed the acquisition of Velocitude LLC (Velocitude).

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments
Company name Apple Inc.
Stock ticker AAPL
Live stock price [stckqut]AAPL[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $602.59
Target stock price (averages with growth) $893.69
Target stock price (averages with no growth) $677.7
Target stock price (manual assumptions) $585.42

The following company description is from Google Finance: http://www.google.com/finance?q=aapl

Apple Inc. (Apple) designs, manufactures and markets a range of personal computers, mobile communication and media devices, and portable digital music players, and sells a range of related software, services, peripherals, networking solutions, and third-party digital content and applications. It’s products and services include Macintosh (Mac) computers, iPhone, iPad, iPod, Apple TV, Xserve, a portfolio of consumer and professional software applications, the Mac OS X and iOS operating systems, third-party digital content and applications through the iTunes Store, and a range of accessory, service and support offerings. The Company sells its products globally through its retail stores, online stores, and direct sales force and third-party cellular network carriers, wholesalers, retailers, and value-added resellers. As of September 25, 2010, the Company had opened a total of 317 retail stores, including 233 stores in the United States and 84 stores internationally.

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

By:
On:
In: Good company, Stock analysis
Tagged:
With: 0 Comments
Company name Express Scripts, Inc.
Stock ticker ESRX
Live stock price [stckqut]ESRX[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $58.78
Target stock price (averages with growth) $79.58
Target stock price (averages with no growth) $63.99
Target stock price (manual assumptions) $55.88

The following company description is from Google Finance: http://www.google.com/finance?q=esrx

Express Scripts, Inc. is a pharmacy benefit management (PBM) operating in North America, offering a range of services to its clients, which include health maintenance organizations (HMOs), health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and Government health programs. The Company has organized its operations into two business segments based on products and services offered: PBM and Emerging Markets (EM). The Company,s revenues are generated from the delivery of prescription drugs through its contracted network of retail pharmacies, home delivery and specialty pharmacy services and EM services. In October 2010, the Company completed the spinoff of its Rx Outreach business unit. In November 2010, the Company announced the formation of Express Scripts Specialty Benefit Services, a specialty benefits company.

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.